Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK

This publication has 27 references indexed in Scilit:

• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
  Published by Elsevier ,2009
• Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study
  British Journal of Cancer, 2008
• Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study
  BMJ, 2008
• An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
  Vaccine, 2008
• Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial
  British Journal of Cancer, 2008
• Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination
  JNCI Journal of the National Cancer Institute, 2008
• Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial
  The Lancet, 2007
• Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis
  The Lancet Infectious Diseases, 2007
• Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update
  International Journal of Cancer, 2007
• High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
  British Journal of Cancer, 2006